119 related articles for article (PubMed ID: 24357304)
1. Medicine. A common pathway for a rare disease?
Vafai SB; Mootha VK
Science; 2013 Dec; 342(6165):1453-4. PubMed ID: 24357304
[No Abstract] [Full Text] [Related]
2. Neurometabolic disease: Treating mitochondrial diseases with mTOR inhibitors--a potential treatment for Leigh syndrome?
Geach T
Nat Rev Neurol; 2014 Jan; 10(1):2. PubMed ID: 24296657
[No Abstract] [Full Text] [Related]
3. mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome.
Johnson SC; Yanos ME; Kayser EB; Quintana A; Sangesland M; Castanza A; Uhde L; Hui J; Wall VZ; Gagnidze A; Oh K; Wasko BM; Ramos FJ; Palmiter RD; Rabinovitch PS; Morgan PG; Sedensky MM; Kaeberlein M
Science; 2013 Dec; 342(6165):1524-8. PubMed ID: 24231806
[TBL] [Abstract][Full Text] [Related]
4. PKC downregulation upon rapamycin treatment attenuates mitochondrial disease.
Martin-Perez M; Grillo AS; Ito TK; Valente AS; Han J; Entwisle SW; Huang HZ; Kim D; Yajima M; Kaeberlein M; Villén J
Nat Metab; 2020 Dec; 2(12):1472-1481. PubMed ID: 33324011
[TBL] [Abstract][Full Text] [Related]
5. Translational Medicine. A target for pharmacological intervention in an untreatable human disease.
Johnson SC
Science; 2014 Dec; 346(6214):1192. PubMed ID: 25477449
[No Abstract] [Full Text] [Related]
6. Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma.
Huelsmann L; Kim DNW; Hannan R; Watumull LM; Brugarolas J
Clin Genitourin Cancer; 2015 Aug; 13(4):e321-e323. PubMed ID: 25620636
[No Abstract] [Full Text] [Related]
7. Inhibition of TORC1 signaling and increased lifespan: gained in translation?
Rallis C; Bähler J
Aging (Albany NY); 2013 May; 5(5):335-6. PubMed ID: 23715437
[No Abstract] [Full Text] [Related]
8. TOR-inhibitors as gero-suppressors.
Nikiforov M
Aging (Albany NY); 2015 Dec; 7(12):1030-1. PubMed ID: 26796970
[No Abstract] [Full Text] [Related]
9. Metabolic regulation, mitochondria and the life-prolonging effect of rapamycin: a mini-review.
Pan Y; Nishida Y; Wang M; Verdin E
Gerontology; 2012; 58(6):524-30. PubMed ID: 22947849
[TBL] [Abstract][Full Text] [Related]
10. Chemoprevention for neurofibromatosis 2: just over the horizon?
Plotkin SR
Neuro Oncol; 2014 Apr; 16(4):471-2. PubMed ID: 24637549
[No Abstract] [Full Text] [Related]
11. Phenotypes associated with inherited and developmental somatic mutations in genes encoding mTOR pathway components.
Saxena A; Sampson JR
Semin Cell Dev Biol; 2014 Dec; 36():140-6. PubMed ID: 25263008
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin enhances survival in a Drosophila model of mitochondrial disease.
Wang A; Mouser J; Pitt J; Promislow D; Kaeberlein M
Oncotarget; 2016 Dec; 7(49):80131-80139. PubMed ID: 27741510
[TBL] [Abstract][Full Text] [Related]
13. Dual Targeting of Akt and mTORC1 Impairs Repair of DNA Double-Strand Breaks and Increases Radiation Sensitivity of Human Tumor Cells.
Holler M; Grottke A; Mueck K; Manes J; Jücker M; Rodemann HP; Toulany M
PLoS One; 2016; 11(5):e0154745. PubMed ID: 27137757
[TBL] [Abstract][Full Text] [Related]
14. Exploring mTOR inhibition as treatment for mitochondrial disease.
Sage-Schwaede A; Engelstad K; Salazar R; Curcio A; Khandji A; Garvin JH; De Vivo DC
Ann Clin Transl Neurol; 2019 Sep; 6(9):1877-1881. PubMed ID: 31386302
[TBL] [Abstract][Full Text] [Related]
15. mTOR pathway inhibitors in cancer therapy: moving past rapamycin.
Wacheck V
Pharmacogenomics; 2010 Sep; 11(9):1189-91. PubMed ID: 20860456
[No Abstract] [Full Text] [Related]
16. Differential effects of mTOR inhibition and dietary ketosis in a mouse model of subacute necrotizing encephalomyelopathy.
Bornstein R; James K; Stokes J; Park KY; Kayser EB; Snell J; Bard A; Chen Y; Kalume F; Johnson SC
Neurobiol Dis; 2022 Feb; 163():105594. PubMed ID: 34933094
[TBL] [Abstract][Full Text] [Related]
17. The Ups and Downs of TORKinibs in Transplantation.
Fantus D; Thomson AW
Transplantation; 2015 Aug; 99(8):e117-8. PubMed ID: 26308303
[No Abstract] [Full Text] [Related]
18. Discovery of Leucyladenylate Sulfamates as Novel Leucyl-tRNA Synthetase (LRS)-Targeted Mammalian Target of Rapamycin Complex 1 (mTORC1) Inhibitors.
Yoon S; Kim JH; Kim SE; Kim C; Tran PT; Ann J; Koh Y; Jang J; Kim S; Moon HS; Kim WK; Lee S; Lee J; Kim S; Lee J
J Med Chem; 2016 Nov; 59(22):10322-10328. PubMed ID: 27933890
[TBL] [Abstract][Full Text] [Related]
19. Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island.
Arriola Apelo SI; Lamming DW
J Gerontol A Biol Sci Med Sci; 2016 Jul; 71(7):841-9. PubMed ID: 27208895
[TBL] [Abstract][Full Text] [Related]
20. Targeting the mTOR pathway in breast cancer.
Liu J; Li HQ; Zhou FX; Yu JW; Sun L; Han ZH
Tumour Biol; 2017 Jun; 39(6):1010428317710825. PubMed ID: 28639903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
